Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will examine the safety and efficacy NPI-002 intravitreal implants post vitrectomy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Single NPI-002 Intravitreal Implant | Experimental | one NPI-002 implant inserted at the time of vitrectomy |
|
| Double NPI-002 Intravitreal Implant | Experimental | two NPI-002 implants inserted at the time of vitrectomy |
|
| Control | No Intervention | No implant inserted at time of vitrectomy |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| NPI-002 Intravitreal Implant | Drug | Implant inserted during vitrectomy. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Lens Densitometry | Change from Baseline | 6 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jami R Kern, PhD | Nacuity Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Royal Adelaide Hospital | Adelaide | Australia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002386 | Cataract |
| ID | Term |
|---|---|
| D007905 | Lens Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided